A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Wang, Emily, Ph.D. Bookmark and Share

Laboratory of S. Emily Wang, Ph.D.

Outsmarting Breast Cancer
Breast carcinogenesis is a multi-event process that occurs in a dynamic microenvironment. Unlike normal differentiated cells whose functions are under tight regulation, cancer cells are multitasking as a result of the hyperactivation of multiple intracellular signaling pathways and loss of tumor suppressors. In cancer cells, these pathways do not respond to normal regulatory signals but are manipulated simultaneously by more than one oncogenic signals. Besides these alterations in cancer cells, modification of the extracellular matrix and transformation of the stromal tissues are also involved in tumor progression and metastasis. Therefore, our rationale to suppress tumor progression includes: 1) simultaneous targeting of key oncogenic pathways expressed in cancer cells, and 2) targeting microenvironmental modifications that result from the crosstalk between oncogenic signaling networks in cancer cells.

Micromanagement of cancer translatome by microRNAs
MicroRNAs (miRNAs) are naturally occurring non-coding small RNA molecules of 21-24 nucleotides that can base pair to 3’UTR sites in the messenger RNAs (mRNAs) of protein-coding genes. Consistent with their regulatory function, miRNAs are crucial for development, differentiation, proliferation and apoptosis. In animals, each miRNA can downregulate the expression from hundreds of target mRNAs via mRNA degradation or block of translation. MiRNAs are frequently dysregulated in human cancers, and have shown promise as tissue-based markers for cancer classification and prognostication. Our group is actively investigating the mechanisms of miRNA dysregulation in breast cancer.

Developing novel microRNA blood markers of breast cancer
MiRNAs have been recently detected in the circulation of cancer patients, where they are associated with clinical parameters. Assessment of circulating miRNA profiles from breast cancer patients and correlation of these profiles with tumor traits (e.g., chemotherapy response) are therefore of great clinical interest. We have carried out discovery profiling of circulating small RNAs by deep sequencing using the pre-treatment sera of stage II–III breast cancer patients. More than 800 miRNA species were detected and exhibited patterns associated with the histopathological and molecular profiles of breast cancer. Our study indicates that certain miRNAs can serve as potential blood-based biomarkers for the clinical outcomes of breast cancer, and developing miRNA blood markers may allow optimized chemotherapy treatments and preventive anti-metastasis interventions in future clinical applications.

Co-evolution of the tumor microenvironment and cancer stem cells (CSCs)
The critical roles of CSCs in cancer initiation, progression and therapeutic refractoriness have emerged in recent studies. Their regulation by factors in the tumor microenvironment, however, remains largely uncharacterized. Our group focuses on various environmental elements, such as the stromal fibroblasts, for their effect on breast cancer stem cells. We show that compared to normal fibroblasts, primary cancer-associated fibroblasts produce higher levels of chemokine (C-C motif) ligand 2 (CCL2), which stimulates the stem-cell-specific, sphere-forming phenotype in breast cancer cells and CSC self-renewal. Increased CCL2 expression in activated fibroblasts requires STAT3 activation by diverse cancer-secreted cytokines, and in turn, induces NOTCH1 expression and the CSC features in breast cancer cells, constituting a “cancer-stroma-cancer” signaling circuit. Our results are supported by a xenograft model of paired fibroblasts and tumor cells from primary human breast cancer. Regulation of NOTCH1 by CCL2 is further supported by a significant correlation between the expression profiles of the two genes in primary breast cancers, where upregulation of both genes is associated with poor differentiation. We are currently exploring the role of CCL2, STAT3 and NOTCH1 as potential therapeutic targets to block the cancer-host communication that prompts CSC-mediated disease progression and treatment resistance.
 
For more information on Dr. Wang, please click here.
 

Wang, Emily, Ph.D.

Laboratory of S. Emily Wang, Ph.D.

Outsmarting Breast Cancer
Breast carcinogenesis is a multi-event process that occurs in a dynamic microenvironment. Unlike normal differentiated cells whose functions are under tight regulation, cancer cells are multitasking as a result of the hyperactivation of multiple intracellular signaling pathways and loss of tumor suppressors. In cancer cells, these pathways do not respond to normal regulatory signals but are manipulated simultaneously by more than one oncogenic signals. Besides these alterations in cancer cells, modification of the extracellular matrix and transformation of the stromal tissues are also involved in tumor progression and metastasis. Therefore, our rationale to suppress tumor progression includes: 1) simultaneous targeting of key oncogenic pathways expressed in cancer cells, and 2) targeting microenvironmental modifications that result from the crosstalk between oncogenic signaling networks in cancer cells.

Micromanagement of cancer translatome by microRNAs
MicroRNAs (miRNAs) are naturally occurring non-coding small RNA molecules of 21-24 nucleotides that can base pair to 3’UTR sites in the messenger RNAs (mRNAs) of protein-coding genes. Consistent with their regulatory function, miRNAs are crucial for development, differentiation, proliferation and apoptosis. In animals, each miRNA can downregulate the expression from hundreds of target mRNAs via mRNA degradation or block of translation. MiRNAs are frequently dysregulated in human cancers, and have shown promise as tissue-based markers for cancer classification and prognostication. Our group is actively investigating the mechanisms of miRNA dysregulation in breast cancer.

Developing novel microRNA blood markers of breast cancer
MiRNAs have been recently detected in the circulation of cancer patients, where they are associated with clinical parameters. Assessment of circulating miRNA profiles from breast cancer patients and correlation of these profiles with tumor traits (e.g., chemotherapy response) are therefore of great clinical interest. We have carried out discovery profiling of circulating small RNAs by deep sequencing using the pre-treatment sera of stage II–III breast cancer patients. More than 800 miRNA species were detected and exhibited patterns associated with the histopathological and molecular profiles of breast cancer. Our study indicates that certain miRNAs can serve as potential blood-based biomarkers for the clinical outcomes of breast cancer, and developing miRNA blood markers may allow optimized chemotherapy treatments and preventive anti-metastasis interventions in future clinical applications.

Co-evolution of the tumor microenvironment and cancer stem cells (CSCs)
The critical roles of CSCs in cancer initiation, progression and therapeutic refractoriness have emerged in recent studies. Their regulation by factors in the tumor microenvironment, however, remains largely uncharacterized. Our group focuses on various environmental elements, such as the stromal fibroblasts, for their effect on breast cancer stem cells. We show that compared to normal fibroblasts, primary cancer-associated fibroblasts produce higher levels of chemokine (C-C motif) ligand 2 (CCL2), which stimulates the stem-cell-specific, sphere-forming phenotype in breast cancer cells and CSC self-renewal. Increased CCL2 expression in activated fibroblasts requires STAT3 activation by diverse cancer-secreted cytokines, and in turn, induces NOTCH1 expression and the CSC features in breast cancer cells, constituting a “cancer-stroma-cancer” signaling circuit. Our results are supported by a xenograft model of paired fibroblasts and tumor cells from primary human breast cancer. Regulation of NOTCH1 by CCL2 is further supported by a significant correlation between the expression profiles of the two genes in primary breast cancers, where upregulation of both genes is associated with poor differentiation. We are currently exploring the role of CCL2, STAT3 and NOTCH1 as potential therapeutic targets to block the cancer-host communication that prompts CSC-mediated disease progression and treatment resistance.
 
For more information on Dr. Wang, please click here.
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • White button mushrooms seem fairly innocuous as fungi go. Unlike portabellas, they don’t center stage at the dinner table, and unlike truffles, they’re not the subject of gourmand fervor. But appearances can be deceiving when it comes to these mild-mannered Clark Kents of the food world. In a study ...
  • Doctors often recommend preventive screenings for several cancers, based on hereditary or genetic factors, but brain tumors aren’t one of them. Primary brain tumors, which originate in the brain rather than spreading from another location, seem to develop at random, and doctors have little insight into wh...
  • Stopping cancer starts with research. To that end, STOP CANCER has awarded $525,000 in grants to City of Hope for 2015, supporting innovative research projects and recognizing the institution’s leadership in advancing cancer treatment and prevention. Founded in 1988, STOP CANCER underwrites the work of le...
  • Cancer may not be the disease many people think it is. Normally, cancer is considered to be a disease in which cells multiply at an extremely high, and unusual, rate – increasing the likelihood of genetic mutations. But increasingly, leading researchers at City of Hope and elsewhere are contending that cancer i...
  • “Of all forms of inequality, injustice in the health care system is the most shocking and inhumane.” By the time the Rev. Martin Luther King Jr. spoke those words in Chicago in 1966, the Civil Rights Act had been passed, the Voting Rights Act was the law of the land and the March on Washington was […]
  • Eight years ago, Matthew Loscalzo surprised himself by accepting the offer to become City of Hope’s administrative director of the Sheri & Les Biller Patient and Family Resource Center and executive director of the Department of Supportive Care Medicine. At the time, he was administrative director of the Sc...
  • The mental fog that patients can experience after undergoing chemotherapy treatment for cancer has a name: “chemo brain.” “Many patients report hearing or reading about chemotherapy-related cognitive deficits, but few are actually prepared to deal with these changes,” said Celina Lemon, M.A., an occupational th...
  • Cancer treatments have improved over the years, but one potential source of treatments and cures remains largely untapped: nature. Blueberries, cinnamon, xinfeng, grape seed (and skin) extract, mushrooms, barberry and pomegranates all contain compounds with the potential to treat or prevent cancer. Scientists a...
  • In the U.S., there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate and lung, according to the American Cancer Society. Each year, 5 million people are treated for skin cancer. Here, Hans Schoellhammer, M.D., assistant clinical professor at City of Hope | Ant...
  • As public health experts know, health improvement starts in the community. Now, City of Hope  has been recognized for its efforts to improve the lives of residents of its own community. The institution will receive funding from the Institute for Healthcare Improvement  to support promising community-based work ...
  • For almost four decades, blood cancer survivors who received bone marrow, or stem cell, transplants have returned to City of Hope to celebrate life, second chances and science. The first reunion, in 1976, was a small affair: spaghetti for a single patient, his brother who served as his donor and those who took ...
  • Chemotherapy is an often-essential component of cancer treatment, attacking cells that divide quickly and helping stop cancer’s advance. But the very characteristics that make chemotherapy effective against cancer also can make it toxic to healthy cells, leading to side effects such as hair loss, nausea, ...
  • When you want to understand how to enhance the patient experience, go straight to the source: The patients. Patients and their families offer unique perspectives on care and services and can provide valuable insights about what is working well and what is not. That’s why City of Hope turns to them for advice. S...
  • Take it from City of Hope researchers: Medical science isn’t just for scientists, but something the whole family can enjoy. From 1 to 4 p.m. on Saturday, May 16, the institution will offer a variety of educational and fun-filled science and healthy living activities at its second Community Science Festiva...
  • Attention, parents! Only a few serious sunburns can increase a child’s ultimate risk of skin cancer. Further, some studies suggest that ultraviolet (UV) exposure before the age of 10 is the most important factor for melanoma risk. Here skin cancer expert Jae Jung, M.D., Ph.D., assistant professor in the D...